Alembic Pharmaceuticals on Monday said the US health regulator has issued one observation after inspection of Karakhadi facility of its joint venture Aleor Dermaceuticals.
Aleor Dermaceuticals is a 60:40 joint venture between Alembic and Orbicular Pharmaceutical Technologies, it said in a filing to BSE.
The United States Food and Drug Administration (USFDA) carried out the inspection of Aleor Dermaceuticals' formulation manufacturing facility at Karakhadi in Gujarat from September 15-20, 2019, it added.
The regulator issued one observation after the inspection, Alembic said. It however did not provide any details about the nature of the observation.
Shares of Alembic Pharma were trading at Rs 546.35 per scrip on BSE, up 5.52 per cent from the previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app